8-K: Cyclacel Pharmaceuticals to Acquire Fitters Sdn. Bhd. in Share Exchange Deal

Cyclacel Pharmaceuticals will acquire Fitters Sdn. Bhd., a Malaysian fire safety company, in a share exchange agreement, issuing 19.99% of its common stock to Fitters Diversified Berhad.

Summary

• Cyclacel Pharmaceuticals, Inc. has entered into a share exchange agreement with FITTERS Diversified Berhad and FITTERS Sdn. Bhd.
• Fitters Parent will exchange 100% of its ownership interest in Fitters for 19.99% of Cyclacel's outstanding common stock.
• Following the closing, Fitters will become a wholly-owned subsidiary of Cyclacel.
• Datuk Dr. Doris Wong Sing Ee, Cyclacel's CEO, will be appointed as a director of Fitters and its subsidiaries.
• The transaction is subject to customary closing conditions, including stockholder approval, Nasdaq listing application, and SEC registration statement effectiveness.
• Either party can terminate the agreement if the transaction is not closed by August 31, 2025.
• Cyclacel will rename to Bio Green Med Solution, Inc.
• Cyclacel stockholders will own approximately 80.01% of the combined company at closing.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The announcement details a strategic acquisition, which is generally viewed favorably. However, there are inherent risks and uncertainties associated with the transaction, preventing a higher sentiment score.

Positives

• Cyclacel gains a wholly-owned subsidiary in Fitters Sdn. Bhd., expanding its business portfolio.
• Fitters gains access to the US stock market.
• Cyclacel will be renamed Bio Green Med Solution, Inc.
• The Boards of Directors of each of Cyclacel, FITTERS and Fitters Sub have unanimously approved the Exchange Agreement.

Negatives

• Existing Cyclacel stockholders will experience dilution as 19.99% of the company's stock will be issued to Fitters Diversified Berhad.
• The deal is subject to various approvals and conditions, creating uncertainty about its completion.
• Cyclacel will be renamed Bio Green Med Solution, Inc.

Risks

• The transaction may not close if required approvals are not obtained or closing conditions are not met.
• Failure to realize the anticipated benefits of the proposed transaction.
• The combined company may face challenges in growing and managing its growth effectively.
• There are risks relating to the uncertainty of the projected financial information with respect to Fitters Sub.
• The combined company may face challenges in meeting Nasdaqs listing standards prior to and following the consummation of the proposed Transaction.

Future Outlook

Cyclacel expects its common shares to continue to be listed on the Nasdaq Capital Market under a new ticker symbol and to be renamed Bio Green Med Solution, Inc. upon closing of the transaction.

Industry Context

This announcement reflects a trend of companies seeking growth and diversification through strategic acquisitions and international expansion. Cyclacel, a biopharmaceutical company, is diversifying its portfolio by acquiring a company in the fire safety and protective equipment industry.

Comparison to Industry Standards

• It is difficult to compare this transaction to industry standards as it is a cross-industry merger between a biopharmaceutical company and a fire safety equipment supplier.
• Comparable transactions would typically involve companies within the same sector, allowing for easier benchmarking of valuation multiples and strategic fit.
• However, the deal structure, involving a share exchange for 19.99% of Cyclacel's equity, is a common method for smaller acquisitions.

Management Changes

Stakeholder Impact

• Shareholders of Cyclacel will experience dilution.
• Employees of Fitters Sdn. Bhd. will become part of Cyclacel.
• Customers of Fitters Sdn. Bhd. will now be served by a subsidiary of Cyclacel.

Next Steps

• Cyclacel needs to call a meeting of its stockholders to approve the Transaction.
• Cyclacel needs to file a listing of additional shares application with The Nasdaq Capital Market.
• Cyclacel needs to file a registration statement on Form S-4 to register the Exchange Shares and the effectiveness of such Form S-4.
• Fitters Parent needs to comply with all applicable requirements under the Bursa Malaysia stock exchange.
• The Company and Fitters Parent must agree to the amount of the Exchange Shares in writing as of the closing date.

Key Dates

Keywords

share exchange, acquisition, Fitters Sdn. Bhd., Cyclacel Pharmaceuticals, Bio Green Med Solution, merger, Nasdaq, FITTERS Diversified Berhad